JUNSHI BIO: March 2026 Monthly Return Confirms Stable Share Capital and No Share Movements

Bulletin Express04-02

Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its monthly return for the period ended 31 March 2026, reporting no changes in either H-share or A-share capital and confirming compliance with Hong Kong public-float requirements.

Authorised / Registered Capital • Total registered capital remained at 1.03 billion shares, split into 260.30 million H shares and 766.39 million A shares, each with a par value of RMB 1.00. • No increase or decrease was recorded during the month.

Issued Shares and Public Float • Issued H shares stood unchanged at 260.30 million, with zero treasury H shares. • Issued A shares were steady at 765.58 million, while 0.82 million A shares continue to be held in treasury. • The company confirmed that the H-share public float exceeds the 5 percent threshold required for PRC issuers with multiple listings.

Treasury Shares • No H-share or A-share repurchases, cancellations, or transfers occurred in March 2026.

Employee Share-Based Incentives • H-share option scheme (approved 29 September 2025): 13.21 million options outstanding; no exercises in March. • A-share option scheme (approved 29 September 2025): 24.70 million options outstanding; no exercises in March. • Aggregate headroom under both schemes totals 65.04 million shares (64.23 million H; 0.82 million A).

Other Instruments • The issuer had no warrants, convertible securities, or other agreements that could lead to share issuance during the month.

Overall, JUNSHI BIO maintained a stable capital structure throughout March 2026, with neither share issuances nor repurchases and full adherence to listing-rule requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172887262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172887262","market":"hk","top_or_hot":-1,"title":"JUNSHI BIO: March 2026 Monthly Return Confirms Stable Share Capital and No Share Movements","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its monthly return for the period ended 31 March 2026, reporting no changes in either H-share or A-share capital and confirming compliance with Hong Kong public-float requirements.</p>\n<p>Authorised / Registered Capital  \n• Total registered capital remained at 1.03 billion shares, split into 260.30 million H shares and 766.39 million A shares, each with a par value of RMB 1.00.  \n• No increase or decrease was recorded during the month.</p>\n<p>Issued Shares and Public Float  \n• Issued H shares stood unchanged at 260.30 million, with zero treasury H shares.  \n• Issued A shares were steady at 765.58 million, while 0.82 million A shares continue to be held in treasury.  \n• The company confirmed that the H-share public float exceeds the 5 percent threshold required for PRC issuers with multiple listings.</p>\n<p>Treasury Shares  \n• No H-share or A-share repurchases, cancellations, or transfers occurred in March 2026.</p>\n<p>Employee Share-Based Incentives  \n• H-share option scheme (approved 29 September 2025): 13.21 million options outstanding; no exercises in March.  \n• A-share option scheme (approved 29 September 2025): 24.70 million options outstanding; no exercises in March.  \n• Aggregate headroom under both schemes totals 65.04 million shares (64.23 million H; 0.82 million A).</p>\n<p>Other Instruments  \n• The issuer had no warrants, convertible securities, or other agreements that could lead to share issuance during the month.</p>\n<p>Overall, JUNSHI BIO maintained a stable capital structure throughout March 2026, with neither share issuances nor repurchases and full adherence to listing-rule requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JUNSHI BIO: March 2026 Monthly Return Confirms Stable Share Capital and No Share Movements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJUNSHI BIO: March 2026 Monthly Return Confirms Stable Share Capital and No Share Movements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-02 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its monthly return for the period ended 31 March 2026, reporting no changes in either H-share or A-share capital and confirming compliance with Hong Kong public-float requirements.</p>\n<p>Authorised / Registered Capital  \n• Total registered capital remained at 1.03 billion shares, split into 260.30 million H shares and 766.39 million A shares, each with a par value of RMB 1.00.  \n• No increase or decrease was recorded during the month.</p>\n<p>Issued Shares and Public Float  \n• Issued H shares stood unchanged at 260.30 million, with zero treasury H shares.  \n• Issued A shares were steady at 765.58 million, while 0.82 million A shares continue to be held in treasury.  \n• The company confirmed that the H-share public float exceeds the 5 percent threshold required for PRC issuers with multiple listings.</p>\n<p>Treasury Shares  \n• No H-share or A-share repurchases, cancellations, or transfers occurred in March 2026.</p>\n<p>Employee Share-Based Incentives  \n• H-share option scheme (approved 29 September 2025): 13.21 million options outstanding; no exercises in March.  \n• A-share option scheme (approved 29 September 2025): 24.70 million options outstanding; no exercises in March.  \n• Aggregate headroom under both schemes totals 65.04 million shares (64.23 million H; 0.82 million A).</p>\n<p>Other Instruments  \n• The issuer had no warrants, convertible securities, or other agreements that could lead to share issuance during the month.</p>\n<p>Overall, JUNSHI BIO maintained a stable capital structure throughout March 2026, with neither share issuances nor repurchases and full adherence to listing-rule requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1172887262","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172887262","pubTimestamp":1775120652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its monthly return for the period ended 31 March 2026, reporting no changes in either H-share or A-share capital and confirming compliance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物：2026年3月月报表确认股本稳定无股份变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) filed its monthly return for the period ended 31 March 2026, reporting no changes in either H-share or A-share capital and confirming compliance with Hong Kong public-float requirements.\nAuthorised / Registered Capital  \n• Total registered capital remained at 1.03 billion shares, split into 260.30 million H shares and 766.39 million A shares, each with a par value of RMB 1.00.  \n• No increase or decrease was recorded during the month.\nIssued Shares and Public Float  \n• Issued H shares stood unchanged at 260.30 million, with zero treasury H shares.  \n• Issued A shares were steady at 765.58 million, while 0.82 million A shares continue to be held in treasury.  \n• The company confirmed that the H-share public float exceeds the 5 percent threshold required for PRC issuers with multiple listings.\nTreasury Shares  \n• No H-share or A-share repurchases, cancellations, or transfers occurred in March 2026.\nEmployee Share-Based Incentives  \n• H-share option scheme (approved 29 September 2025): 13.21 million options outstanding; no exercises in March.  \n• A-share option scheme (approved 29 September 2025): 24.70 million options outstanding; no exercises in March.  \n• Aggregate headroom under both schemes totals 65.04 million shares (64.23 million H; 0.82 million A).\nOther Instruments  \n• The issuer had no warrants, convertible securities, or other agreements that could lead to share issuance during the month.\nOverall, JUNSHI BIO maintained a stable capital structure throughout March 2026, with neither share issuances nor repurchases and full adherence to listing-rule requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172887262","isCrawlerRequest":true}